08.12.09
Mark D. Young, Ph.D. has been named senior vice president of Pharmaceutical Operations at Alder Biopharmaceuticals. Dr. Young brings more than 30 years experience in the process development and manufacturing of biopharmaceuticals produced from yeast, bacterial and mammalian cells. This includes expertise in engineering, technology transfer, manufacturing and clinical development at a number of prominent biotechnology companies including Zymogenetics, Biomira (now Oncothyreon), Protein Design Labs and Synergen (acquired by Amgen).
“Mark’s breadth of bioprocessing experience and leadership will be instrumental to Alder in the continued application of our high throughput antibody selection and yeast production systems to streamline the identification and production of best-in-class biotherapeutics,” said Randall Schatzman, Ph.D., chief executive officer of Alder. “With our recent success of ALD518 in Phase II trials for treatment of RA, Mark’s late-stage manufacturing experience will be key as we gear up to initiate Phase III trials and plan for commercial manufacturing.”
Dr. Young most recently served as a bioprocess consultant, providing technical and strategic consulting on issues of bioprocess development and manufacturing for a variety of biopharmaceutical clients. Prior to that, Young he was senior vice president, Technical Operations for Zymogenetics from 2001 to 2006, where he was responsible for process development, analytical development, formulation development and stability, manufacturing, and quality functions. During his tenure, Young and his group successfully filed chemistry, manufacturing and control (CMC) sections of investigational new drug applications for three products, managed outsourcing for these products and established in-house clinical manufacturing capabilities.
“Mark’s breadth of bioprocessing experience and leadership will be instrumental to Alder in the continued application of our high throughput antibody selection and yeast production systems to streamline the identification and production of best-in-class biotherapeutics,” said Randall Schatzman, Ph.D., chief executive officer of Alder. “With our recent success of ALD518 in Phase II trials for treatment of RA, Mark’s late-stage manufacturing experience will be key as we gear up to initiate Phase III trials and plan for commercial manufacturing.”
Dr. Young most recently served as a bioprocess consultant, providing technical and strategic consulting on issues of bioprocess development and manufacturing for a variety of biopharmaceutical clients. Prior to that, Young he was senior vice president, Technical Operations for Zymogenetics from 2001 to 2006, where he was responsible for process development, analytical development, formulation development and stability, manufacturing, and quality functions. During his tenure, Young and his group successfully filed chemistry, manufacturing and control (CMC) sections of investigational new drug applications for three products, managed outsourcing for these products and established in-house clinical manufacturing capabilities.